{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-343407","form_type":"8-K","ticker":"UPB","cik":"0002022626","company_name":"Upstream Bio, Inc.","filed_at":"2026-08-11T11:05:23+00:00","discovered_at":"2026-08-11T11:10:00.404220+00:00","generated_at":"2026-08-11T11:10:43.897108+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Upstream Bio Q2 net loss $39.7M; cash $261.3M funds through 2027; Phase 3 on track","bullets":["Net loss of $39.7M for Q2 2026 vs $40.0M year ago; R&D spend $36.1M, G&A $7.1M.","Cash and equivalents of $261.3M as of June 30, 2026, expected to fund operations through 2027.","Phase 3 trials in severe asthma and CRSwNP on track to initiate Q1 2027; FDA End-of-Phase 2 meetings on schedule.","Completed enrollment in Phase 2 VENTURE COPD trial (481 participants); data expected H2 2027.","Phase 2 data: ~80% of verekitug-treated CRSwNP patients achieved NPS improvement; ERS late-breaking data Sept 5-9."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-343407","json":"https://secwatch.observer/filing/0001193125-26-343407.json","markdown":"https://secwatch.observer/filing/0001193125-26-343407.md","text":"https://secwatch.observer/filing/0001193125-26-343407.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022626/000119312526343407/0001193125-26-343407-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022626/000119312526343407/upb-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T11:10:43.897108+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}